New & Improved!

Submit a New & Noteworthy
April 2019
Therapeutic Drug Monitoring Antibodies
By: Bio-Rad Laboratories, Inc

Bio-Rad Laboratories has launched a range of recombinant monoclonal anti-idiotypic antibodies that inhibit the binding of the drug eculizumab (Soliris) to its target, complement C5 protein, and therefore detect free drug for use in drug-level monitoring assays. This new range comprises four inhibitory antibodies that are highly specific for the humanized IgG2/4 kappa monoclonal antibody drug, eculizumab, a biotherapeutic used to treat paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. The anti-eculizumab inhibitory antibodies can be used to quantify the level of eculizumab in patient samples. An antibody pair is ideal for the development of a pharmacokinetic bridging ELISA, and three antibodies of high, medium, and low affinity are suitable as a positive control or calibrator in an anti-drug antibody assay.

Bio-Rad Laboratories, Inc

Click here to view product detail on Findit.

Current Issue

Enter our Sweepstakes now for your chance to win the following prizes:

    Just answer the following quick question for your chance to win:

    To continue, you must either login or register:

    As of May 24, 2018,'s Terms of Use and Privacy Policy have been updated.
    You can review the Terms of Use HERE and the Privacy Policy HERE.
    By continuing to use, you are agreeing to these changes.